English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Behandlung einer serösen makulären Netzhautablösung mit Antihistaminika

MPS-Authors
/persons/resource/persons84015

Kirschfeld,  K
Former Department Comparative Neurobiology, Max Planck Institute for Biological Cybernetics, Max Planck Society;

Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Kirschfeld, K. (2015). Behandlung einer serösen makulären Netzhautablösung mit Antihistaminika. Der Ophthalmologe, 112(1), 57-60. doi:10.1007/s00347-014-3096-y.


Cite as: http://hdl.handle.net/11858/00-001M-0000-002A-4783-C
Abstract
The etiology of retinal detachment in central serous retinopathy (CSR) is unknown; however, three facts are generally accepted: (1) the serous exudate which raises the layers of the receptors/pigment epithelium is formed due to hyperpermeability in the choriocapillaries, (2) patients frequently suffer from headaches and (3) stress promotes the incidence of CSR. A high blood plasma histamine concentration can cause the abovementioned symptoms which suggests that histamine might provoke CSR. Within 1 week after administration of the antihistamine loratadin a considerable reduction in the retinal exudate and restoration of vision were observed. This supports the hypothesis that histamine could be involved in the process of retinal detachment. Further investigations and large scale clinical trials should clarify if this hypothesis can be proved or disproved and whether antihistamines can be used for age-related macular degeneration (AMD).